Sugi Predict

Sugi Predict / Compounds / SCHEMBL3130708

SCHEMBL3130708

SCHEMBL3130708

CC(C)(C)OC(=O)NC1CCN(c2ccc(N)cc2)CC1

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ CKS1B P61024 1/20 0.52
▸ SKP1 P63208 1/20 0.52
▸ SKP2 Q13309 1/20 0.52
▸ GPR119 Q8TDV5 5/20 0.48
▸ CTSK P43235 2/20 0.48
▸ KCNA3 P22001 1/20 0.47
▸ DRD2 P14416 3/20 0.46
▸ SUV39H2 Q9H5I1 1/20 0.46
▸ CASP6 P55212 1/20 0.46
▸ GFER P55789 1/20 0.46
▸ KDM1A O60341 1/20 0.45
▸ MAOB P27338 1/20 0.45
▸ NAMPT P43490 1/20 0.45
▸ CNR1 P21554 1/20 0.45
▸ CNR2 P34972 1/20 0.45
▸ MAP4K4 O95819 2/20 0.44
▸ PIM1 P11309 1/20 0.44
▸ PIM3 Q86V86 1/20 0.44
▸ PIM2 Q9P1W9 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3708015 0.92 CTSK (0.52) CKS1BSKP1SKP2CTSKSUV39H2
SCHEMBL30981429 0.89 KCNA3 (0.54) CKS1BSKP1SKP2KCNA3DRD2
SCHEMBL32665409 0.89 ME3 (0.54) CKS1BSKP1SKP2GPR119CTSK
SCHEMBL5204853 0.88 GPR119 (0.63) CKS1BSKP1SKP2GPR119CTSK
SCHEMBL3108407 0.88 CNR1 (0.55) CKS1BSKP1SKP2GPR119CTSK
SCHEMBL5216885 0.88 CHRM4 (0.53) CKS1BSKP1SKP2GPR119CTSK
SCHEMBL16682477 0.88 CKS1B (0.51) CKS1BSKP1SKP2GPR119CTSK
SCHEMBL17830852 0.88 CKS1B (0.61) CKS1BSKP1SKP2GPR119CTSK
SCHEMBL26452282 0.87 CKS1B (0.51) CKS1BSKP1SKP2GPR119CTSK
SCHEMBL14892758 0.87 CKS1B (0.48) CKS1BSKP1SKP2GPR119CTSK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12570626-B2 Degraders and degrons for targeted protein degradation C4 THERAPEUTICS, INC. (US) 2026-03-10 — — US disclosed
US-20230357180-A1 DEGRADERS AND DEGRONS FOR TARGETED PROTEIN DEGRADATION C4 THERAPEUTICS, INC. (US) 2023-11-09 — — US disclosed
US-20230357180-A1 DEGRADERS AND DEGRONS FOR TARGETED PROTEIN DEGRADATION C4 THERAPEUTICS, INC. (US) 2023-11-09 — — US disclosed
US-20230357180-A1 DEGRADERS AND DEGRONS FOR TARGETED PROTEIN DEGRADATION C4 THERAPEUTICS, INC. (US) 2023-11-09 — — US disclosed
US-20230145336-A1 BRAF DEGRADERS C4 THERAPEUTICS, INC. (US) 2023-05-11 — — US disclosed
US-20230145336-A1 BRAF DEGRADERS C4 THERAPEUTICS, INC. (US) 2023-05-11 — — US disclosed
WO-2023066363-A1 PARP-1 DEGRADATION AGENT AND USE THEREOF 海思科医药集团股份有限公司 2023-04-27 — — WO disclosed
EP-4168407-A1 BRAF DEGRADERS C4 Therapeutics, Inc. (US) 2023-04-26 — — EP disclosed
US-11524949-B2 Degraders and Degrons for targeted protein degradation C4 THERAPEUTICS, INC. (US) 2022-12-13 — — US disclosed
WO-2021255212-A1 BRAF DEGRADERS F. HOFFMANN-LA ROCHE AG (CH) 2021-12-23 — — WO disclosed
US-20090137545-A1 Compounds BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-05-28 — — US disclosed
WO-2009021758-A1 ARYLSULFONAMIDES HAVING AN ANALGESIC EFFECT BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-02-19 — — WO disclosed
WO-2009021946-A1 NOVEL COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-02-19 — — WO disclosed
EP-2025675-A1 Arylsulfonamides with analgetic activity Boehringer Ingelheim International GmbH (DE) 2009-02-18 — — EP disclosed
WO-2008139161-A1 OXAZOLE TYROSINE KINASE INHIBITORS SAREUM LIMITED (GB) 2008-11-20 — — WO disclosed
WO-2008139161-A1 OXAZOLE TYROSINE KINASE INHIBITORS SAREUM LIMITED (GB) 2008-11-20 — — WO disclosed
WO-2008022945-A1 ARYL SULFONAMIDES WITH AN ANALGESIC ACTION BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2008-02-28 — — WO disclosed
US-20070213355-A1 1H-Imidazo[4,5-C]Quinoline Derivatives in the Treatment of Protein Kinase Dependent Diseases CAPRARO HANS-GEORG 2007-09-13 — — US disclosed
EP-1689747-A1 1H-IMIDAZO [4,5-C] QUINOLINE DERIVATIVES IN THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES Novartis AG (CH) 2006-08-16 — — EP disclosed
WO-2005054238-A1 1H-IMIDAZO[4,5-C]QUINOLINE DERIVATIVES IN THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES NOVARTIS AG (CH) 2005-06-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090137545-A1 Compounds ADORA2B, ABCB11, CYP11B1 CKS1B 2935/4885SKP1 2470/4885SKP2 3935/4885
US-12570626-B2 Degraders and degrons for targeted protein degradation ADRM1, UCHL3, USP30 CKS1B 1676/4885SKP1 2722/4885SKP2 582/4885
US-20230145336-A1 BRAF DEGRADERS BRAF, NRAS, RAF1 CKS1B 543/4885SKP1 1123/4885SKP2 146/4885
US-20070213355-A1 1H-Imidazo[4,5-C]Quinoline Derivatives in the Treatment of Protein Kinase Dependent Diseases ABL1, PRKCA, PRKCQ CKS1B 193/4885SKP1 701/4885SKP2 467/4885
US-20230357180-A1 DEGRADERS AND DEGRONS FOR TARGETED PROTEIN DEGRADATION STUB1, MDM2, USP30 CKS1B 1781/4885SKP1 1480/4885SKP2 251/4885
US-11524949-B2 Degraders and Degrons for targeted protein degradation STUB1, MDM2, USP30 CKS1B 1781/4885SKP1 1480/4885SKP2 251/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback